Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 101–200 of 1,000
The Epidemiology of Intracerebral Hemorrhage in the United States from 1979 to 2008
Rincón, F., & Mayer, S. A. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9793-y · Cited by 140
“Similarly, the changes and disparities in hospital mortality, which are in part substantiated by data from recent clinical trials [28, 29], need to be investigated by future studies that will compare the effectiveness of care related to survival and disposition within ICH and other types of stroke.”
ResultSelf-citationSteiner, T., Purrucker, J. C., de Sousa, D. A., Apostolaki‐Hansson, T., Beck, J., Christensen, H., Cordonnier, C., Downer, M. B., Eilertsen, H., Gartly, R., et al. (2025) · European Stroke Journal · doi:10.1177/23969873251340815 · Cited by 164
Self-citationManagement of Prehospital Antiplatelet and Anticoagulant Therapy in Traumatic Head Injury: A Review
McMillian, W. D., & Rogers, F. B. (2009) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181978e7b · Cited by 140
Saver, J. L. (2011) · Stroke · doi:10.1161/strokeaha.111.619122 · Cited by 148
Predicting Intracerebral Hemorrhage Growth With the Spot Sign: The Effect of Onset-to-Scan Time
Dowlatshahi, D. D., Brouwers, H. B., Demchuk, A. M., Hill, M. D., Aviv, R. I., Ufholz, L., Reaume, M., Wintermark, M., Hemphill, J. C., Murai, Y., et al. (2016) · Stroke · doi:10.1161/strokeaha.115.012012 · Cited by 143
Self-citationNaidech, A. M., Liebling, S. M., Rosenberg, N. F., Lindholm, P. F., Bernstein, R. A., Batjer, H. H., Alberts, M. J., & Kwaan, H. C. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9619-3 · Cited by 135
“Studies of acute treatment of ICH such as acute blood pressure control [3] and activated factor VII [4] necessarily focus on reducing hemorrhage growth as the proximate mechanism.”
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH): Rationale and Design
Qureshi, A. I. (2007) · Neurocritical Care · doi:10.1385/ncc:6:1:56 · Cited by 140
Blood Pressure Reduction, Decreased Diffusion on MRI, and Outcomes After Intracerebral Hemorrhage
Garg, R. K., Liebling, S. M., Maas, M. B., Nemeth, A. J., Russell, E. J., & Naidech, A. M. (2011) · Stroke · doi:10.1161/strokeaha.111.629493 · Cited by 136
Off-Label Use of Recombinant Factor VIIa in U.S. Hospitals: Analysis of Hospital Records
Logan, A. C., Yank, V. A., & Stafford, R. S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00002 · Cited by 130
Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage
Al‐Kawaz, M., Hanley, D. F., & Ziai, W. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00902-w · Cited by 139
Hematoma Expansion in Intracerebral Hemorrhage: An Update on Prediction and Treatment
Li, Z., You, M., Long, C., Bi, R., Xu, H., He, Q., & Hu, B. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00702 · Cited by 145
“conducted two successive trials, Factor Seven For Hemorrhagic Stroke-1, 2 (FAST-1, 2), both of which demonstrated recombinant factor VIIa (RFVIIa), can reduce HE but showed opposite results in clinical outcomes (152, 153).”
BackgroundProgressing haemorrhagic stroke: categories, causes, mechanisms and managements
Chen, S., Zeng, L., & Hu, Z. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7291-1 · Cited by 161
Bösel, J., Niesen, W., Salih, F., Morris, N. A., Ragland, J. T., Gough, B., Schneider, H., Neumann, J., Hwang, D. Y., Kantamneni, P. C., et al. (2022) · JAMA · doi:10.1001/jama.2022.4798 · Cited by 140
Self-citationHigh Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods
Yeatts, S. D., Palesch, Y. Y., Moy, C. S., & Selim, M. H. (2013) · Neurocritical Care · doi:10.1007/s12028-013-9861-y · Cited by 125
Full medical support for intracerebral hemorrhage
Morgenstern, L. B., Zahuranec, D. B., Sánchez, B. N., Becker, K. J., Geraghty, M., Hughes, R., Norris, G. M., & Hemphill, J. C. (2015) · Neurology · doi:10.1212/wnl.0000000000001525 · Cited by 125
Drip and Ship Versus Direct to Comprehensive Stroke Center
Holodinsky, J. K., Williamson, T. S., Kamal, N. R., Mayank, D., Hill, M. D., & Goyal, M. (2016) · Stroke · doi:10.1161/strokeaha.116.014306 · Cited by 124
Matrix Metalloproteinases in Acute Intracerebral Hemorrhage
Lattanzi, S., Napoli, M. D., Ricci, S., & Divani, A. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00839-0 · Cited by 126
Gladstone, D. J., Aviv, R. I., Demchuk, A. M., Hill, M. D., Thorpe, K. E., Khoury, J. C., Sucharew, H. J., Al-Ajlan, F. S., Butcher, K., Dowlatshahi, D. D., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2636 · Cited by 123
Self-citationShoamanesh, A., Lindsay, M. P., Castellucci, L. A., Cayley, A., Crowther, M. A., de Wit, K., English, S. W., Hoosein, S., Huynh, T. J., Kelly, M., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493020968424 · Cited by 141
Diringer, M. N., Skolnick, B. E., Mayer, S. A., Steiner, T., Davis, S. M., Brun, N. C., & Broderick, J. P. (2010) · Stroke · doi:10.1161/strokeaha.109.561712 · Cited by 122
Self-citationSex Differences in Incidence, Pathophysiology, and Outcome of Primary Intracerebral Hemorrhage
Gokhale, S., Caplan, L. R., & James, M. L. (2015) · Stroke · doi:10.1161/strokeaha.114.007682 · Cited by 128
Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention
Seiffge, D. J., Fandler‐Höfler, S., Du, Y., Goeldlin, M. B., Jolink, W. M. T., Klijn, C. J. M., & Werring, D. J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01035-w · Cited by 130
“Future research is needed to show whether CLAS-ICH or CADMUS provide clinical benefit.”
Acute Brain Infarcts After Spontaneous Intracerebral Hemorrhage: A Diffusion-Weighted Imaging Study
Prabhakaran, S., Gupta, R., Ouyang, B., John, S., Temes, R. E., Mohammad, Y., Lee, V. H., & Bleck, T. P. (2010) · Stroke · doi:10.1161/strokeaha.109.566257 · Cited by 119
Intensive blood pressure reduction in acute intracerebral hemorrhage: A meta-analysis
Tsivgoulis, G., Katsanos, A. H., Butcher, K. S., Boviatsis, E., Triantafyllou, N., Rizos, I., & Alexandrov, A. V. (2014) · Neurology · doi:10.1212/wnl.0000000000000917 · Cited by 110
Recent advances in spontaneous intracerebral hemorrhage
Garg, R., & Biller, J. (2019) · F1000Research · doi:10.12688/f1000research.16357.1 · Cited by 129
Liu, J., Xu, H., Chen, Q., Zhang, T., Sheng, W., Huang, Q., Song, J., Huang, D., Li, L., Li, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.040 · Cited by 113
“Reducing hematomagrowth andmortality is the current focus of clinical trials, such as INTERACT [6], ATACHII [7], STOP-AUST [8], FAST [9], STOP-IT [10], and SPOTLIGHT [10].”
BackgroundProthrombin Complex Concentrates for Bleeding in the Perioperative Setting
Ghadimi, K., Levy, J. H., & Welsby, I. J. (2016) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001188 · Cited by 112
Ischemic Brain Injury After Intracerebral Hemorrhage: A Critical Review
Prabhakaran, S., & Naidech, A. M. (2012) · Stroke · doi:10.1161/strokeaha.112.655910 · Cited by 112
New ischemic lesions coexisting with acute intracerebral hemorrhage
Kang, D.-W., Han, M.-K., Kim, H.-J., Yun, S.-C., Jeon, S.-B., Bae, H.-J., Kwon, S. U., & Kim, J. S. (2012) · Neurology · doi:10.1212/wnl.0b013e3182648a79 · Cited by 109
O’Carroll, C. B., Brown, B. L., & Freeman, W. D. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.10.034 · Cited by 121
Management of Thrombolysis-Associated Symptomatic Intracerebral Hemorrhage
Goldstein, J. N., Marrero, M., Masrur, S., Pervez, M. A., Barrocas, A. M., Abdullah, A. R., Олейник, А. О., Rosand, J. M., Smith, E. E., Dzik, S., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.175 · Cited by 117
Leal-Noval, S. R., Múñoz, M., Asuero, M., Contreras, E., García‐Erce, J. A., Llau, J. V., Moral, V., Páramo, J. A., & Quintana, M. (2013) · Europe PMC (PubMed Central) · doi:10.2450/2013.0029-13 · Cited by 135
Christensen, M. C., Mayer, S. A., & Ferran, J.-M. (2009) · Stroke · doi:10.1161/strokeaha.108.538967 · Cited by 103
“Edema volume, mL (SD) 13 (13) 12 (14) 0.”
Self-citationPeak perihemorrhagic edema correlates with functional outcome in intracerebral hemorrhage
Volbers, B., Giede-Jeppe, A., Gerner, S. T., Sembill, J. A., Kuramatsu, J. B., Lang, S. T., Lücking, H., Staykov, D., & Huttner, H. B. (2018) · Neurology · doi:10.1212/wnl.0000000000005167 · Cited by 111
“PHE evolution was not analyzed in this trial.(8) Another approach targeting multiple pathophysiologic pathways associated with PHE evolution is therapeutic hypothermia.”
BackgroundPostcontrast CT Extravasation Is Associated With Hematoma Expansion in CTA Spot Negative Patients
Ederies, A., Demchuk, A. M., Chia, T. L., Gladstone, D. J., Dowlatshahi, D. D., Bendavit, G. G., Wong, K., Symons, S. P., & Aviv, R. I. (2009) · Stroke · doi:10.1161/strokeaha.108.541201 · Cited by 102
Location-Specific Hematoma Volume Cutoff and Clinical Outcomes in Intracerebral Hemorrhage
Teo, K. C., Fong, S.-M., Leung, W. C. Y., Leung, I. Y. H., Wong, Y., Choi, O. M. Y., Yam, K., Lo, R., Cheung, R. T. F., Ho, S.-L., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.041246 · Cited by 102
Newell, D. W., Shah, M. M., Wilcox, R., Hansmann, D. R., Melnychuk, E. M., Muschelli, J., & Hanley, D. F. (2011) · Journal of neurosurgery · doi:10.3171/2011.5.jns10505 · Cited by 113
Oral anticoagulant-associated intracerebral hemorrhage
Cervera, Á., Amaro, S., & Chamorro, Á. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6153-3 · Cited by 109
“This observation has encouraged the design of clinical trials aimed at improving outcome at expenses of limiting secondary hematoma growth [22].”
BackgroundMethodComparison of Outcomes after Intracerebral Hemorrhage and Ischemic Stroke
Chiu, D. T. W., Peterson, L. E., Elkind, M. S. V., Rosand, J. M., Gerber, L. M., & Silverstein, M. D. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2009.06.002 · Cited by 100
Intracranial Hemorrhage in Patients with Cancer
Velander, A. J., DeAngelis, L. M., & Navi, B. B. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0250-3 · Cited by 99
Management of Spontaneous Intracerebral Hemorrhage
Veltkamp, R. C., & Purrucker, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0783-5 · Cited by 104
Qureshi, A. I., Huang, W., Lobanova, I., Barsan, W. G., Hanley, D. F., Hsu, C. Y., Lin, C.-L., Silbergleit, R., Steiner, T., Suarez, J. I., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3075 · Cited by 96
Self-citationBershad, E. M., & Suárez, J. I. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9310-0 · Cited by 98
“The use of rFVIIa for intracranial bleeding has been increasing in the United States; however randomized data do not yet support its clinical efficacy in unselected patients with ICH [24, 25].”
BackgroundClinical review: Critical care management of spontaneous intracerebral hemorrhage
Rincón, F., & Mayer, S. A. (2008) · Critical Care · doi:10.1186/cc7092 · Cited by 116
Self-citationBrouwers, H. B., Goldstein, J. N., Romero, J. M., & Rosand, J. M. (2012) · Stroke · doi:10.1161/strokeaha.112.664003 · Cited by 99
Maddox, W. R., Kay, G. N., Yamada, T., Osorio, J., Doppalapudi, H., Plumb, V. J., Gunter, A., & McElderry, H. T. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12143 · Cited by 94
Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis
Zehtabchi, S., Baki, S. G. A., Falzon, L., & Nishijima, D. K. (2014) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2014.09.023 · Cited by 100
Matrix Metalloproteinases in Human Spontaneous Intracerebral Hemorrhage: An Update
Florczak‐Rzepka, M., Grond‐Ginsbach, C., Montaner, J., & Steiner, T. (2012) · Cerebrovascular Diseases · doi:10.1159/000341686 · Cited by 93
Self-citationSecondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage
Bautista, W., Adelson, P. D., Bicher, N., Themistocleous, M. S., Tsivgoulis, G. K., & Chang, J. J. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211049208 · Cited by 95
Kosior, J. C., Idris, S., Dowlatshahi, D. D., Alzawahmah, M., Eesa, M., Sharma, P., Tymchuk, S., Hill, M. D., Aviv, R. I., Frayne, R., et al. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00579.x · Cited by 92
Early Progression of Traumatic Cerebral Contusions: Characterization and Risk Factors
White, C. L., Griffith, S., & Caron, J.-L. R. (2009) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181b2519f · Cited by 92
The Story of Intracerebral Hemorrhage: From Recalcitrant to Treatable Disease
Broderick, J. P., Grotta, J. C., Naidech, A. M., Steiner, T., Sprigg, N., Toyoda, Ḱ., Dowlatshahi, D. D., Demchuk, A. M., Selim, M. H., Mocco, J., et al. (2021) · Stroke · doi:10.1161/strokeaha.121.033484 · Cited by 99
Self-citationMinocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study
Chang, J. J., Kim‐Tenser, M. A., Emanuel, B. A., Jones, G. M., Chapple, K. M., Alikhani, A., Sanossian, N., Mack, W. J., Tsivgoulis, G. K., Alexandrov, A. V., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13403 · Cited by 92
“Major trials have targeted primary hematoma volume through various mechanisms including hematoma evacuation [2], hemostasis [3] and acute blood pressure control [4,5], but have failed to improve clinical outcome.”
BackgroundRatcliff, J. J., Hall, A. J., Porto, E., Saville, B. R., Lewis, R. J., Allen, J. W., Frankel, M., Wright, D. W., Barrow, D. L., & Pradilla, G. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1126958 · Cited by 90
“An effective therapy for ICH patients has been elusive despite several well-designed clinical trials focused on surgical evacuation (6, 7), hemostasis augmentation (8), and blood-pressure reduction (9–11), among other interventions, all of which have failed to improve functional outcomes.”
BackgroundPrehospital stroke care: New prospects for treatment and clinical research
Audebert, H. J., Saver, J. L., Starkman, S., Lees, K. R., & Endres, M. (2013) · Neurology · doi:10.1212/wnl.0b013e31829e0fdd · Cited by 98
Mendiratta, S., hussein, M., Nasser, H. A., & Ali, A. (2019) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201900195 · Cited by 95
Specogna, A. V., Turin, T. C., Patten, S. B., & Hill, M. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096743 · Cited by 95
“Several studies have investigated hypertensive treatments as well as other potential therapies for ICH; many of which were designed to identify and treat ICH progression [5,6].”
BackgroundPrevalence and Characterization of ECG Abnormalities After Intracerebral Hemorrhage
van Bree, Roos, Y. B. W. E. M., van der Bilt, I. A. C., Wilde, A. A. M., Sprengers, M. E. S., de Gans, K., & Vergouwen, M. D. I. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9283-z · Cited by 96
“VIIa treatment. Recombinant factor VIIa treatment in a dosage of 80 lg/kg can lead to ST segment elevation myocardial infarction [ 31 ].”
BackgroundApolipoprotein E Genotype Predicts Hematoma Expansion in Lobar Intracerebral Hemorrhage
Brouwers, H. B., Biffi, A., Ayres, A. M., Schwab, K. M., Cortellini, L., Romero, J. M., Rost, N. S., Viswanathan, A., Greenberg, S. M., Rosand, J. M., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.643262 · Cited by 98
Huynh, T. J., Aviv, R. I., Dowlatshahi, D. D., Gladstone, D. J., Laupacis, A., Kiss, A., Hill, M. D., Molina, C. A., Rodríguez‐Luna, D., Dzialowski, I., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.009893 · Cited by 94
Lim-Hing, K., & Rincón, F. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00074 · Cited by 97
“The study found no significant difference in the proportion of patients with death or severe disability (mRS 5–6) at 90 days, but the hemostatic effect and adverse effect profiles were replicated (63).”
BackgroundPredictors of 30-day mortality in patients with spontaneous primary intracerebral hemorrhage
Safatli, D. A., Günther, A., Schlattmann, P., Schwarz, F., Kalff, R., & Ewald, C. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.187493 · Cited by 88
“Optimal management is still under discussion and subject of many studies in the medical literature dealing inter alia with various treatment options[1,14] and potential predictive models.”
BackgroundArima, H., Anderson, C. S., Wang, J. G., Huang, Y., Heeley, E. L., Neal, B. C., Woodward, M., Skulina, C., Parsons, M. W., Peng, B., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.154328 · Cited by 97
CT Angiography for Intracerebral Hemorrhage Does Not Increase Risk of Acute Nephropathy
Oleinik, A., Romero, J. M., Schwab, K. M., Lev, M. H., Jhawar, N., Almandoz, J. E. D., Smith, E. E., Greenberg, S. M., Rosand, J. M., & Goldstein, J. N. (2009) · Stroke · doi:10.1161/strokeaha.108.546127 · Cited by 86
Small Intracerebral Haemorrhages are Associated with Less Haematoma Expansion and Better Outcomes
Dowlatshahi, D. D., Smith, E. E., Flaherty, M. L., Ali, M., Lyden, P. D., Demchuk, A. M., & Collaborators, O. B. O. T. V. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00563.x · Cited by 86
Kollmar, R., Jüettler, E., Huttner, H. B., Dörfler, A., Staykov, D., Kallmuenzer, B., Schmutzhard, E., Schwab, S., Broessner, G., & for the CINCH investigators (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00707.x · Cited by 86
Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage
Rosell, A., Vilalta, A., García-Berrocoso, T., Fernández-Cadenas, I., Domingues-Montanari, S., Cuadrado, E., Delgado, P., Ribó, M., Martínez-Sáez, E., Ortega-Aznar, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016750 · Cited by 83
“Promising clinical trials have recently failed to demonstrate longterm benefits by preventing hematoma expansion using recombinant activated Factor VII (rFVIIa) [2], although a subset of younger patients without extensive bleeding at baseline can benefit from rFVIIa if given within 2.”
BackgroundEmergency Neurological Life Support: Intracerebral Hemorrhage
Jauch, E. C., Pineda, J., & Hemphill, J. C. (2015) · Neurocritical Care · doi:10.1007/s12028-015-0167-0 · Cited by 86
“The rFVIIa has been shown to decrease hematoma growth in non-coagulopathic ICH patients, but this did not translate into improved clinical outcome [32].”
BackgroundBrouwers, H. B., Falcone, G. J., McNamara, K. A., Ayres, A. M., Олейник, А. О., Schwab, K. M., Romero, J. M., Viswanathan, A., Greenberg, S. M., Rosand, J. M., et al. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9765-2 · Cited by 84
Perihematomal edema: Implications for intracerebral hemorrhage research and therapeutic advances
Selim, M. H., & Norton, C. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24372 · Cited by 83
Experimental Intracerebral Hemorrhage: Avoiding Pitfalls in Translational Research
Kirkman, M. A., Allan, S. M., & Parry-Jones, A. R. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.124 · Cited by 83
“However, while a subsequent phase III clinical trial of recombinant factor VIIa confirmed its ability to reduce hematoma growth, it failed to improve survival or functional outcome following ICH (Mayer et al, 2008).”
Boulouis, G., van Etten, E. S., Charidimou, A., Auriel, E., Morotti, A., Pasi, M., Haley, K. E., Brouwers, H. B., Ayres, A. M., Vashkevich, A., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2619 · Cited by 83
Li, H., Wei, J., Xia, W., Li, J.-H., Liu, A., Yin, S.-B., Wang, C., Song, L., Wang, Y., Zheng, G., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.139 · Cited by 86
Current Status of Pharmacologic Therapies in Patient Blood Management
Goodnough, L. T., & Shander, A. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318273f4ae · Cited by 83
Challenges for intraventricular hemorrhage research and emerging therapeutic targets
Garton, T. P., Hua, Y., Xiang, J., Xi, G., & Keep, R. F. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1397628 · Cited by 86
Naidech, A. M. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0475ci · Cited by 92
Potential Role of Blood Biomarkers in the Management of Nontraumatic Intracerebral Hemorrhage
Senn, R., Elkind, M. S. V., Montaner, J., Christ‐Crain, M., & Mira, K. (2014) · Cerebrovascular Diseases · doi:10.1159/000366470 · Cited by 90
Intracranial hemorrhage in adult patients with hematological malignancies
Chen, C., Tai, C., Cheng, A., Wu, H., Tsay, W., Liu, J., Chen, P.-Y., Huang, S., Yao, M., Tang, J., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-97 · Cited by 81
Vaglio, S., Prisco, D., Biancofiore, G., Rafanelli, D., Antonioli, P., Lisanti, M., Andreani, L., Basso, L., Velati, C., Grazzini, G., et al. (2016) · PubMed · doi:10.2450/2015.0172-15 · Cited by 98
Lavigne-Lissalde, G., Aya, A. G. M., Mercier, F. J., Roger-Christoph, S., Chauleur, C., Morau, E., Ducloy‐Bouthors, A. ‐., Mignon, A., Raucoules, M., Bongain, A., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12844 · Cited by 86
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 93
“(CETP inhibitors, discussed later), hemorrhagic stroke (recombinant factor VIIa that failed to improve clinical outcomes) (6), where bio-”
BackgroundRoux, P. L., Pollack, C. V., Milan, M., & Schaefer, A. W. (2014) · Journal of neurosurgery · doi:10.3171/2014.8.paradigm · Cited by 83
Du, F., Jiang, R., Gu, M., He, C., & Guan, J. X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115777 · Cited by 82
“It represents a considerable unmet medical need despite recent advances [1, 2].”
BackgroundHemostatic and hemorrhagic problems in neurosurgical patients
Gerlach, R., Krause, M., Seifert, V., & Goerlinger, K. (2009) · Acta Neurochirurgica · doi:10.1007/s00701-009-0409-z · Cited by 82
“the risk of thromboembolic events, the preconditions for use of rFVIIa, as well as alternatives to obtain hemostasis— like fibrinogen and PCC administration, have to be considered [58, 122, 206, 208, 290].”
BackgroundSprigg, N., Renton, C., Dineen, R. A., Kwong, Y., & Bath, P. M. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.11.007 · Cited by 79
“Although phase II study of FVIIa appeared promising,(10) the subsequent and larger FAST trial was neutral with respect to functional outcome.(11) Ameta-analysis of these and other trials of hemostatic therapies was similarly neutral.”
ResultBelur, P. K., Chang, J. J., He, S., Emanuel, B. A., & Mack, W. J. (2013) · Neurosurgical FOCUS · doi:10.3171/2013.2.focus1317 · Cited by 80
Leal-Noval, S. R., Múñoz, M., Asuero, M., Contreras, E., García‐Erce, J. A., Llau, J. V., Moral, V., Páramo, J. A., Quintana, M., Basora, M., et al. (2013) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2012.12.003 · Cited by 91
Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients
Beshay, J. E., Morgan, H. W., Madden, C. J., Yu, W., & Sarode, R. (2009) · Journal of neurosurgery · doi:10.3171/2009.7.jns0982 · Cited by 78
microRNAs in Cerebrovascular Disease
Volný, O., Kašičková, L., Coufalová, D., Cimflová, P., & Novák, J. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22671-2_9 · Cited by 79
An emerging role of mast cells in cerebral ischemia and hemorrhage
Strbian, D., Kovanen, P. T., Karjalainen-Lindsberg, M.-L., Tatlisumak, T., & Lindsberg, P. J. (2009) · Annals of Medicine · doi:10.1080/07853890902887303 · Cited by 77
“In contrast to ischemic stroke, no widely approved clinical therapy (5,6) exists for intracerebral”
BackgroundClinical review: Traumatic brain injury in patients receiving antiplatelet medication
Beynon, C., Hertle, D. N., Unterberg, A. W., & Sakowitz, O. W. (2012) · Critical Care · doi:10.1186/cc11292 · Cited by 77
“The drug was evaluated in the therapy of spon taneous ICH, but its application did not improve survival or functional outcome, despite reducing haema toma growth [47].”
BackgroundGuha, S., Sethi, R., Ray, S., Bahl, V. K., Shanmugasundaram, S., Kerkar, P. G., Ramakrishnan, S., Yadav, R. K., Chaudhary, G. K., Kapoor, A., et al. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.03.006 · Cited by 89
Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage
Kuramatsu, J. B., Sembill, J. A., & Huttner, H. B. (2019) · Critical Care · doi:10.1186/s13054-019-2492-8 · Cited by 79
Reade, M. C., Delaney, A., Bailey, M. J., & Angus, D. C. (2008) · Critical Care · doi:10.1186/cc6941 · Cited by 72
“trial of activated factor VII that hypothesised a 33% relative improvement in outcome for patients with acute intracerebral haemorrhage [37].”
BackgroundMatrix Metalloproteinase-9: Dual Role and Temporal Profile in Intracerebral Hemorrhage
Chang, J. J., Emanuel, B. A., Mack, W. J., Tsivgoulis, G., & Alexandrov, A. V. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2014.07.005 · Cited by 76
“Agents such as factor VII attenuated ICH growth and remained promising in small phase I-II clinical trials,(16) but carried substantial risk of thromboembolic complications in higher dosing groups,(17,18) and ultimately did not improve clinical outcome in a phase III trial.(19) Despite advances in the control of prima…”
Backgroundthe PATCH Investigators, de Gans, K., de Haan, R. J., Majoie, C. B. L. M., Koopman, M. M. W., Brand, A., Dijkgraaf, M. G. W., Vermeulen, M., & Roos, Y. B. W. E. M. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-19 · Cited by 75
Meretoja, A., Churilov, L. P., Campbell, B. C. V., Aviv, R. I., Yassi, N., Barras, C. D., Mitchell, P. J., Yan, B., Nandurkar, H. H., Bladin, C., et al. (2013) · International Journal of Stroke · doi:10.1111/ijs.12132 · Cited by 79
Self-citationZheng, Y., Hu, Q., Manaenko, A., Zhang, Y., Peng, Y., Xu, L., Tang, J., Tang, J., & Zhang, J. H. (2014) · Stroke · doi:10.1161/strokeaha.114.006372 · Cited by 75
Leasure, A. C., Qureshi, A. I., Murthy, S. B., Kamel, H., Goldstein, J. N., Woo, D., Ziai, W., Hanley, D. F., Salman, R. A., Matouk, C. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1141 · Cited by 78
Brunkhorst, R., Pfeilschifter, W., & Foerch, C. (2010) · Translational Stroke Research · doi:10.1007/s12975-010-0040-6 · Cited by 74
“Several treatment options for acute ICH are currently evaluated in large clinical trials including blood pressure lowering [4], reversal of warfarin anticoagulation [5], and the administration of hemostatic agents [6].”
Background
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.